Is Healthpeak Properties (DOC) a risky stock?
As of July 21, 2026, Clavix grades Healthpeak Properties (DOC) B for risk, a composite score of 74 out of 100 on an A+ to F scale, which puts DOC in the "solid" band. The grade is a risk read for educational purposes, not a buy or sell recommendation.
Grade as of July 21, 2026. Clavix regrades every trading day.
The five risk dimensions behind DOC's grade
Each Clavix grade is a composite of five independent reads. Higher is safer. Here is how DOC scores on each, as of July 21, 2026.
What's moving DOC's risk right now
Company-specific signals Clavix flags behind DOC's current grade, drawn from recent news and filings as of July 21, 2026.
Wells Fargo raised its Healthpeak price target to $22 but kept an equal weight rating, meaning it sees the stock as fairly valued. A new stake from Independent Financial Group and a routine SEC filing leave the picture mixed with no clear catalyst.
Healthpeak is partnering with Brookfield in a $2.1 billion joint venture covering a large portion of its outpatient medical real estate portfolio. The deal is designed to unlock capital and strengthen DOC's balance sheet.
The $2.1 billion outpatient medical joint venture with Brookfield gives Healthpeak about $1.025 billion in cash while keeping operational control and management fees. The proceeds can fund new investments or pay down debt.
What a B grade means
On the Clavix A+ to F scale, DOC's composite of 74 falls in the B band (65–79), read as "solid." The scale is fixed, so the meaning never moves.
This page is generated from Clavix's own risk model and is for educational purposes only. It is not investment advice or a recommendation to buy or sell DOC or any security. Grades are risk indicators, not predictions of return. Data may be delayed.